Every 10-Q that iRhythm Holdings, Inc. (IRTC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IRTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRTC filings page.
iRhythm Holdings, Inc. reported higher Q1 2026 revenue but remained unprofitable. Revenue rose to $199.4 million, up from $158.7 million a year earlier, driven mainly by contracted commercial payors and Medicare. Net loss narrowed to $13.9 million, or $0.43 per share, compared with a $30.7 million loss, reflecting improved operating leverage.
The company ended the quarter with $240.1 million in cash and cash equivalents and $309.5 million in marketable securities, against $661.3 million of 1.50% senior convertible notes due 2029. Adjusted EBITDA turned positive at $14.1 million versus a negative $2.6 million a year earlier.
iRhythm continues to invest in internal-use software, strategic investments (including loans to BioIntelliSense), and stock-based compensation, while managing credit losses and contractual allowances on receivables. The company also discloses ongoing securities, patent, and government matters and states it is cooperating with authorities and defending these cases.
iRhythm Technologies (IRTC) reported strong top-line growth with narrowed losses. For the three months ended September 30, 2025, revenue was $192.9 million versus $147.5 million a year ago, and gross profit was $137.1 million versus $101.5 million. Loss from operations improved to $8.4 million from $50.3 million, and net loss was $5.2 million compared with $46.2 million. Net loss per share was $0.16 versus $1.48.
Year to date, revenue reached $538.2 million and operating cash flow was $54.7 million. The balance sheet showed cash and cash equivalents of $255.6 million and marketable securities of $309.6 million, with total assets of $995.2 million. Long‑term senior convertible notes stood at $648.8 million (carrying amount). Operating expenses reflected continued investment, including $21.0 million in R&D and $124.2 million in SG&A for the quarter. Shares outstanding were 32,219,143 as of October 23, 2025.